EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis

Deborah M Siegal iD, Nauzer Forbes iD, John Eikelboom iD, Jan Beyer-Westendorf, Alexander T Cohen iD, Lizhen Xu, Stuart J Connolly iD, Mark Crowther

Circulation · 2024

DOI: 10.1161/circulationaha.123.066933 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Circulation, 2024. Verfasst von Deborah M Siegal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Ottawa, Ontario, Canada (D.M.S.). Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Gastrointestinal Hemorrhage. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

espite favorable efficacy and safety profiles of factor Xa (FXa) inhibitor anticoagulants, associated mortality can occur in ≈ 9% of patients within 30 days of major extracranial bleeding, including gastro-intestinal (GI) bleeding. 1 The GI tract is the most common site of major bleeding associated with direct oral anticoagulants, including FXa inhibitors. 2 Andexanet alfa (AA; ANDEXXA [coagulation FXa (recombinant), inactivated zhzo]), a modified recombinant inactive form of human FXa, binds and sequesters FXa inhibitor molecules. In the ANNEXA-4 study (Andexanet Alfa, a Novel Anti-dote to the Anticoagulation Effects of Factor Xa Inhibitors), a prospective, single-arm, open-label study of AA in patients with FXa inhibitor–associated acute major bleeding, hemostasis at 12 hours was adjudicated as good to excellent in 80% of evaluable patients. 3,4 The objectives of this post hoc analysis are to summarize patient characteristics, evaluate effects of AA on anti-FXa activity and hemostatic efficacy, and examine clinical outcomes in the GI bleeding cohort. The ANNEXA-4 study methods have been published previously. 3,4

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor Xa InhibitorsGastrointestinal HemorrhageHumansFactor XaRecombinant ProteinsAnticoagulantsRivaroxaban

Stichwörter der Autor:innen

anticoagulantsfactor Xafactor Xa inhibitorsgastrointestinal hemorrhagehemostasis

Substanzen

Factor Xa InhibitorsPRT064445Factor XaRecombinant ProteinsAnticoagulantsRivaroxaban

Autor:innen und Institutionen

  • Department of Medicine, University of Ottawa, Ontario, Canada (D.M.S.).
  • Department of Medicine, Cumming School of Medicine, University of Calgary, Alberta, Canada (N.F.).
  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada (J.E., M.C.).
  • Department of Medicine I, Division of "Thrombosis & Hemostasis," University Hospital Dresden, Germany (J.B.-W.).
  • Thrombosis and Haemophilia Centre, Guy's and St Thomas' NHS Trust, London, United Kingdom (A.T.C.).
  • Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (L.X., S.J.C.).

ORCID-Profile: Deborah M Siegal, Nauzer Forbes, John Eikelboom, Alexander T Cohen, Stuart J Connolly

Zitieren

APA

Siegal, D. M., Forbes, N., Eikelboom, J., Beyer-Westendorf, J., Cohen, A. T., Xu, L., Connolly, S. J., & Crowther, M. (2024). The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis. Circulation. https://doi.org/10.1161/circulationaha.123.066933

Vancouver

Siegal DM, Forbes N, Eikelboom J, Beyer-Westendorf J, Cohen AT, Xu L, et al. The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis. Circulation. 2024. doi:10.1161/circulationaha.123.066933

BibTeX
@article{Siegal2024,
  author = {Siegal, Deborah M and Forbes, Nauzer and Eikelboom, John and Beyer-Westendorf, Jan and Cohen, Alexander T and Xu, Lizhen and Connolly, Stuart J and Crowther, Mark},
  title = {The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis},
  journal = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.123.066933}
}
Kostenlos starten →